Загрузка...
Ubrogepant: First Approval
Ubrogepant (Ubrelvy™) is an orally administered, small molecule, highly-selective, calcitonin gene-related peptide (CGRP) antagonist that was developed by Allergan under license to Merck & Co. as an acute treatment for migraine. In December 2019, ubrogepant received its first global approval in...
Сохранить в:
| Опубликовано в: : | Drugs |
|---|---|
| Главный автор: | |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Springer International Publishing
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7062659/ https://ncbi.nlm.nih.gov/pubmed/32020557 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-020-01264-5 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|